… was to determine the cardiac effects of dapagliflozin in patients with HF and … ejection fraction
[EF]) using cardiac MRI (CMR). Fifty-six patients were randomized 1:1 to either dapagliflozin …

… of heart failure (HF) in patients with reduced ejection fraction (HFrEF) and with … ejection
fraction (HFpEF), as well as cardiovascular disease [1, 2]. Diabetes-related cardiomyopathy is …

… The effects of empagliflozin and dapagliflozin on hospitalisations for heart failure were
consistent in the two independent trials and suggest that these agents also improve renal …

… (HF) with reduced ejection fraction (HFrEF) has not been widely reported. In this article, the
… dapagliflozin and sacubitril/valsartan respect to improvements of cardiac function in patients …

… in Patients with HF with Reduced Ejection Fraction) trial. Using targeted metabolomics, we
found that dapagliflozin … fatty acid biology with SGLT2is in patients with HFrEF. Leveraging the …

… in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis
that Dapagliflozin would … and venous capacitance during exercise in patients with HFpEF. …

… dapagliflozin resulted in significant reductions in first and recurrent HF hospitalizations in
patients with HF across the left ventricular ejection fraction … the effects of dapagliflozin on HF …

… patients with HF with reduced left ventricular ejection fraction … online randomization platform
and patients were randomized … Patients were randomly assigned to take Dapagliflozin 10 …

… patients with a paced rhythm and cardiac resynchronization therapy. Overall, 4008
patients had heart failure (HF) with reduced ejection fraction (… /preserved ejection fraction (HFmrEF/…

… dapagliflozin significantly decreased the risk of … heart failure or death from cardiovascular
causes in patients with HFrEF [1]. We believe that dapagliflozin is safe and effective in patients …